14th invitation to manufacturers for Expression of Interest (EOI) regarding Reproductive Health medicines.

4 June 2018
14th invitation to manufacturers for Expression of Interest (EOI) regarding Reproductive Health medicines.
 
UNFPA is pleased to invite Manufacturers of Reproductive Health Medicines to submit an Expression of Interest (EOI) for product evaluation by WHO Expert Review Painel (ERP) regarding RH medicines.
 
Products of interest: 
  • Medroxyprogesterone acetate, depot injection 150 mg/ml, in 1-ml vial
  • Depot-medroxyprogesterone acetate (DMPA-SC), subcutaneously administered injection 104mg/0.65mL.
  • Mifepristone 200 mg tablet (only to be used in combination with misoprostol)
  • Mifepristone 200 mg tablet co-packaged with 4 tablets of misoprostol 200 micrograms.
  • Benzathine benzylpenicillin 2.4 million units per dose in vial for reconstitution and intramuscular injection.
The deadline for document submission is 30th July 2018 at 17:00 (Copenhagen Time CEST).
 
Please click on UNGM link below for more information: